{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:00:44Z","timestamp":1790125244769,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0024"],"award-info":[{"award-number":["W81XWH-20-1-0024"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01174-7","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:03:34Z","timestamp":1779181414000},"page":"1261-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance"],"prefix":"10.1038","volume":"7","author":[{"given":"Hui","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihae","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Ran","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4681","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-7647","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.1232227","volume":"339","author":"LM Coussens","year":"2013","unstructured":"Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286\u2013291 (2013).","journal-title":"Science"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","volume":"111","author":"D Metcalf","year":"2008","unstructured":"Metcalf, D. Hematopoietic cytokines. Blood 111, 485\u2013491 (2008).","journal-title":"Blood"},{"key":"1174_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253\u2013268 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1174_CR4","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","volume":"111","author":"K Movahedi","year":"2008","unstructured":"Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233\u20134244 (2008).","journal-title":"Blood"},{"key":"1174_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"1174_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208\u2013220 (2016).","journal-title":"Trends Immunol."},{"key":"1174_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447\u2013462 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D. & Morton, J. P. Therapeutic targeting of tumour myeloid cells. Nat. Rev. Cancer 23, 216\u2013237 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1174_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","volume":"32","author":"I Marigo","year":"2011","unstructured":"Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C\/EBP\u03b2 transcription factor. Immunity 32, 790\u2013802 (2011).","journal-title":"Immunity"},{"key":"1174_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.immuni.2013.06.004","volume":"38","author":"N Sonda","year":"2013","unstructured":"Sonda, N. et al. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 38, 1236\u20131249 (2013).","journal-title":"Immunity"},{"key":"1174_CR12","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.62347\/MUKD2745","volume":"14","author":"YL Li","year":"2024","unstructured":"Li, Y. L., Chen, C. H., Lai, Y. S., Pan, M. R. & Hung, W. C. Increased blood CSF3R+ myeloid-derived suppressor cell is a predictor for breast cancer recurrence. Am. J. Cancer Res. 14, 3171\u20133185 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2015.07.006","volume":"28","author":"L Strauss","year":"2015","unstructured":"Strauss, L. et al. RORC1 regulates tumor-promoting \u2018emergency\u2019 granulo-monocytopoiesis. Cancer Cell 28, 253\u2013269 (2015).","journal-title":"Cancer Cell"},{"key":"1174_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.immuni.2018.02.002","volume":"48","author":"M Evrard","year":"2018","unstructured":"Evrard, M. et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity 48, 364\u2013379 (2018).","journal-title":"Immunity"},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2020.06.005","volume":"53","author":"I Kwok","year":"2020","unstructured":"Kwok, I. et al. Combinatorial single-cell analyses of granulocyte-monocyte progenitor heterogeneity reveals an early uni-potent neutrophil progenitor. Immunity 53, 303\u2013318 (2020).","journal-title":"Immunity"},{"key":"1174_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4227","volume":"361","author":"J Albrengues","year":"2018","unstructured":"Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).","journal-title":"Science"},{"key":"1174_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","volume":"583","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature 583, 133\u2013138 (2020).","journal-title":"Nature"},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"A Teijeira","year":"2020","unstructured":"Teijeira, A. et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity 52, 856\u2013871 (2020).","journal-title":"Immunity"},{"key":"1174_CR19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190354","volume":"217","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J. Exp. Med. 217, e20190354 (2020).","journal-title":"J. Exp. Med."},{"key":"1174_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","volume":"2","author":"S Ugel","year":"2012","unstructured":"Ugel, S. et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2, 628\u2013639 (2012).","journal-title":"Cell Rep."},{"key":"1174_CR21","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu, C. et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J. Clin. Invest. 128, 3425\u20133438 (2018).","journal-title":"J. Clin. Invest."},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.4049\/jimmunol.1103253","volume":"188","author":"S Boettcher","year":"2012","unstructured":"Boettcher, S. et al. Cutting edge: LPS-induced emergency myelopoiesis depends on TLR4-expressing nonhematopoietic cells. J. Immunol. 188, 5824\u20135828 (2012).","journal-title":"J. Immunol."},{"key":"1174_CR23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201803","volume":"218","author":"F Veglia","year":"2021","unstructured":"Veglia, F. et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J. Exp. Med. 218, e20201803 (2021).","journal-title":"J. Exp. Med."},{"key":"1174_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","volume":"5","author":"H Alshetaiwi","year":"2020","unstructured":"Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).","journal-title":"Sci. Immunol."},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature 621, 830\u2013839 (2023).","journal-title":"Nature"},{"key":"1174_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf6493","volume":"383","author":"MSF Ng","year":"2024","unstructured":"Ng, M. S. F. et al. Deterministic reprogramming of neutrophils within tumors. Science 383, eadf6493 (2024).","journal-title":"Science"},{"key":"1174_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber, R. et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front. Immunol. 9, 1310 (2018).","journal-title":"Front. Immunol."},{"key":"1174_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1189\/jlb.1009676","volume":"87","author":"JC Simard","year":"2010","unstructured":"Simard, J. C., Girard, D. & Tessier, P. A. Induction of neutrophil degranulation by S100A9 via a MAPK-dependent mechanism. J. Leukoc. Biol. 87, 905\u2013914 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"1174_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10555-020-09951-1","volume":"40","author":"K Rawat","year":"2021","unstructured":"Rawat, K., Syeda, S. & Shrivastava, A. Neutrophil-derived granule cargoes: paving the way for tumor growth and progression. Cancer Metastasis Rev. 40, 221\u2013244 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"C486","DOI":"10.1152\/ajpcell.00122.2022","volume":"323","author":"JE Strobech","year":"2022","unstructured":"Strobech, J. E., Giuriatti, P. & Erler, J. T. Neutrophil granulocytes influence on extracellular matrix in cancer progression. Am. J. Physiol. Cell Physiol. 323, C486\u2013C493 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1174_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.13176","volume":"314","author":"BB Antuamwine","year":"2023","unstructured":"Antuamwine, B. B. et al. N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol. Rev. 314, 250\u2013279 (2023).","journal-title":"Immunol. Rev."},{"key":"1174_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24591-x","volume":"12","author":"V Mysore","year":"2021","unstructured":"Mysore, V. et al. Fc\u03b3R engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. Nat. Commun. 12, 4791 (2021).","journal-title":"Nat. Commun."},{"key":"1174_CR33","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187, 1422\u20131439 (2024).","journal-title":"Cell"},{"key":"1174_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22973-9","volume":"12","author":"R Grieshaber-Bouyer","year":"2021","unstructured":"Grieshaber-Bouyer, R. et al. The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. Nat. Commun. 12, 2856 (2021).","journal-title":"Nat. Commun."},{"key":"1174_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961601","volume":"13","author":"S Paudel","year":"2022","unstructured":"Paudel, S., Ghimire, L., Jin, L., Jeansonne, D. & Jeyaseelan, S. Regulation of emergency granulopoiesis during infection. Front. Immunol. 13, 961601 (2022).","journal-title":"Front. Immunol."},{"key":"1174_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12440","volume":"273","author":"JB Cowland","year":"2016","unstructured":"Cowland, J. B. & Borregaard, N. Granulopoiesis and granules of human neutrophils. Immunol. Rev. 273, 11\u201328 (2016).","journal-title":"Immunol. Rev."},{"key":"1174_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41590-021-00968-4","volume":"22","author":"TE Khoyratty","year":"2021","unstructured":"Khoyratty, T. E. et al. Distinct transcription factor networks control neutrophil-driven inflammation. Nat. Immunol. 22, 1093\u20131106 (2021).","journal-title":"Nat. Immunol."},{"key":"1174_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104632","volume":"382","author":"S Fujisawa","year":"2022","unstructured":"Fujisawa, S., Nagata, Y. & Suzuki, R. Leukotriene D4 accelerates antigen-mediated mast cell responses via the cysteinyl leukotriene 1 receptor. Cell. Immunol. 382, 104632 (2022).","journal-title":"Cell. Immunol."},{"key":"1174_CR39","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.4049\/jimmunol.1000901","volume":"185","author":"MG Lechner","year":"2010","unstructured":"Lechner, M. G., Liebertz, D. J. & Epstein, A. L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185, 2273\u20132284 (2010).","journal-title":"J. Immunol."},{"key":"1174_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"1174_CR41","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"1174_CR42","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1174_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"1174_CR44","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.6301011","volume":"220","author":"B Samuelsson","year":"1983","unstructured":"Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568\u2013575 (1983).","journal-title":"Science"},{"key":"1174_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ncprheum0375","volume":"3","author":"O Kowal-Bielecka","year":"2007","unstructured":"Kowal-Bielecka, O., Kowal, K., Distler, O. & Gay, S. Mechanisms of disease: leukotrienes and lipoxins in scleroderma lung disease\u2013insights and potential therapeutic implications. Nat. Clin. Pract. Rheumatol. 3, 43\u201351 (2007).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"1174_CR46","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.4049\/jimmunol.173.3.1503","volume":"173","author":"Y Kanaoka","year":"2004","unstructured":"Kanaoka, Y. & Boyce, J. A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 173, 1503\u20131510 (2004).","journal-title":"J. Immunol."},{"key":"1174_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/608930","volume":"2014","author":"AJ Theron","year":"2014","unstructured":"Theron, A. J. et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J. Immunol. Res. 2014, 608930 (2014).","journal-title":"J. Immunol. Res."},{"key":"1174_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood-2006-07-037572","volume":"111","author":"M Buitenhuis","year":"2008","unstructured":"Buitenhuis, M. et al. Protein kinase B (c-AKT) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 111, 112\u2013121 (2008).","journal-title":"Blood"},{"key":"1174_CR49","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1182\/blood-2009-10-246967","volume":"115","author":"M de la Luz Sierra","year":"2010","unstructured":"de la Luz Sierra, M. et al. The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1. Blood 115, 3970\u20133979 (2010).","journal-title":"Blood"},{"key":"1174_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04487-w","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. Cell Death Dis. 13, 36 (2022).","journal-title":"Cell Death Dis."},{"key":"1174_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2007.09.013","volume":"121","author":"G Woszczek","year":"2008","unstructured":"Woszczek, G. et al. Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor. J. Allergy Clin. Immunol. 121, 215\u2013221 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1174_CR52","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jaci.2017.11.026","volume":"142","author":"DS Cheung","year":"2018","unstructured":"Cheung, D. S. et al. Cysteinyl leukotriene receptor 1 expression identifies a subset of neutrophils during the antiviral response that contributes to postviral atopic airway disease. J. Allergy Clin. Immunol. 142, 1206\u20131217 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1174_CR53","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317\u20131334 (2019).","journal-title":"Immunity"},{"key":"1174_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati, L. et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183, 771\u2013785 (2020).","journal-title":"Cell"},{"key":"1174_CR55","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.4049\/jimmunol.1501399","volume":"198","author":"D Dominguez","year":"2017","unstructured":"Dominguez, D. et al. Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J. Immunol. 198, 1365\u20131375 (2017).","journal-title":"J. Immunol."},{"key":"1174_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. CD73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat. Commun. 10, 150 (2019).","journal-title":"Nat. Commun."},{"key":"1174_CR57","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/JCI45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121, 2371\u20132382 (2011).","journal-title":"J. Clin. Invest."},{"key":"1174_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1158\/0008-5472.CAN-14-2331","volume":"75","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 75, 519\u2013531 (2015).","journal-title":"Cancer Res."},{"key":"1174_CR59","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"1174_CR60","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1172\/JCI131992","volume":"130","author":"K Poropatich","year":"2020","unstructured":"Poropatich, K. et al. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J. Clin. Invest. 130, 3528\u20133542 (2020).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01174-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01174-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01174-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:06Z","timestamp":1787321286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01174-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01174-7","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}